Has Cogent Biosciences (COGT) Run Too Far After Wider Losses?
Cogent Biosciences (COGT) recently reported wider losses in Q2 2026, with a net loss of US$96.41 million. Despite a strong 213.21% total shareholder return over the past year, recent momentum has cooled, and the stock's high price-to-book ratio of 14.1x suggests a premium valuation, justified by its peer group but carrying risks related to clinical trials and ongoing losses. The article advises investors to consider the company's future execution and potential risks.
COGT Maintained by Piper Sandler -- Price Target Raised to $55
Piper Sandler has maintained an "Overweight" rating for Cogent Biosciences (COGT) and raised its price target to $55.00, reflecting increased confidence in the company's potential, especially for its precision therapy program CGT9486. Despite this positive analyst outlook, Cogent Biosciences has a low GF Score™ of 30/100 and a high Price-to-Sales ratio of 220.78x, indicating potential overvaluation and challenges in profitability and growth, suggesting investors should proceed with caution.
Has Cogent Biosciences (COGT) Run Too Far After Wider Losses?
Cogent Biosciences (COGT) recently reported wider net losses for Q2 and H1 2026, with a net loss of US$96.41 million for the quarter and US$193.76 million for the half-year. Despite a strong 213.21% total shareholder return over the past year, its 90-day share price return of 21.38% and a recent 7-day decline suggest momentum is cooling. The company's Price-to-Book ratio of 14.1x is high compared to the broader biotech industry but aligns with its closer peers, indicating investors are weighing future pipeline execution and expected revenue growth over current financials.
Why Cogent Biosciences (COGT) Is Down 10.5% After Reporting Wider First-Half 2026 Losses – And What's Next
Cogent Biosciences (COGT) reported wider net losses for Q2 and H1 2026, leading to a 10.5% stock drop. The company's investment narrative is currently focused on cash burn and funding, with future catalysts tied to FDA reviews for bezuclastinib and launch preparedness. Investors are advised to consider the implications of sustained losses on future funding and the company's valuation.
Why Cogent Biosciences (COGT) Is Down 10.5% After Reporting Wider First-Half 2026 Losses – And What's Next
Cogent Biosciences (COGT) reported wider net losses for the second quarter and first half of 2026, leading to a 10.5% drop in its stock price. The company's increasing losses highlight ongoing cost and funding pressures, which may influence investor assessment of its research and development progress. Despite the clinical momentum of its drug, bezuclastinib, the immediate future for Cogent Biosciences is focused on cash burn and funding risks rather than earnings, with financing concerns becoming more pressing following the share price pullback.
Bank of America Corp DE Has $40.18 Million Stock Holdings in Cogent Biosciences, Inc. $COGT
Bank of America Corp DE reduced its stake in Cogent Biosciences, Inc. by 12.6% in the first quarter, selling 150,125 shares but retaining 1,043,805 shares valued at approximately $40.18 million. Cogent Biosciences reported a quarterly loss of $0.52 per share, outperforming analyst expectations. The company currently holds a "Moderate Buy" consensus rating from analysts, with an average price target of $49.10.
Deerfield group discloses 2.88% Cogent Biosciences (COGT) position in amended 13G
A group of Deerfield entities and James E. Flynn have filed an amended Schedule 13G, revealing a collective beneficial ownership of 5,006,104 shares of Cogent Biosciences (COGT) common stock, which represents 2.88% of the outstanding class. The filing indicates shared voting and dispositive power over these shares, and the group now holds 5 percent or less of this class of securities. This disclosure provides transparency on significant ownership stakes in Cogent Biosciences.
Tema ETFs LLC Acquires 64,898 Shares of Cogent Biosciences, Inc. $COGT
Tema ETFs LLC increased its stake in Cogent Biosciences (NASDAQ:COGT) by 36.7% in the second quarter, acquiring an additional 64,898 shares to bring its total holdings to 241,565 shares, valued at approximately $9.35 million. The biopharmaceutical company reported a quarterly loss of $0.52 per share, exceeding analyst expectations, and maintains a "Moderate Buy" consensus rating with an average price target of $45.90. Other institutional investors have also adjusted their positions in Cogent Biosciences, which currently has a market cap of $6.61 billion.
Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of "Moderate Buy" by Brokerages
Cogent Biosciences (NASDAQ:COGT) has received an average "Moderate Buy" recommendation from thirteen brokerages, with an average 12-month price target of $45.90. The company recently reported quarterly EPS of -$0.52, exceeding the consensus estimate. Institutional investors have also increased their holdings in the company.
Cogent Biosciences set to report earnings ahead of FDA decisions
Cogent Biosciences is preparing to release its second-quarter earnings report, with investor attention focused on the company's commercial readiness as it transitions from a clinical-stage to a marketed-drug business. Analysts anticipate a loss of $0.555 per share for the quarter, and the company is advancing regulatory filings for its lead drug candidate, bezuclastinib, for which the FDA has set a target action date of December 30, 2026, for one of its applications. Key areas of interest include updates on commercial launch preparations, regulatory progress, and the company's cash burn trajectory as it builds out its commercial infrastructure.
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results
Cogent Biosciences announced its second-quarter 2026 financial results and recent business highlights. The company is on track for potential FDA approval of its drug bezuclastinib for GIST and NonAdvSM later this year, having submitted three New Drug Applications. Cogent also reported a strong pro forma cash balance of $865.9 million, sufficient to fund operations into late 2028, and detailed progress in its clinical trials and commercial team development.
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results
Cogent Biosciences reported strong second-quarter 2026 financial results and significant business highlights, including progress toward potential FDA approvals for bezuclastinib for GIST and NonAdvSM later this year. The company also announced the successful onboarding of a cross-functional customer-facing team and a robust pro forma cash balance of $865.9 million, expected to fund operations into late 2028. Key clinical data from the PEAK and APEX trials were presented, demonstrating substantial benefits of bezuclastinib in treating GIST and Advanced Systemic Mastocytosis.
Cogent Biosciences (COGT) files prospectus for $400M at-the-market stock program
Cogent Biosciences (COGT) has filed a prospectus supplement for an at-the-market (ATM) stock program, allowing it to offer and sell up to $400 million of its common stock. This program uses an existing automatic shelf registration statement and permits sales through Guggenheim Securities, LLC. The filing establishes capacity for future stock sales but does not represent an immediate issuance or receipt of proceeds.
Cogent Biosciences (NASDAQ: COGT) details cash runway and bezuclastinib FDA timelines
Cogent Biosciences (NASDAQ: COGT) has provided updates on its financial runway and the FDA timelines for its drug bezuclastinib. The company reported a net loss of $96.4 million for Q2 2026, widening from the previous year, but has $792.3 million in cash, cash equivalents, and marketable securities, projected to fund operations into late 2028. Bezuclastinib has three New Drug Applications under FDA review, with PDUFA dates in November and December 2026 for GIST and systemic mastocytosis, respectively, and management anticipates a potential commercial launch in late 2026.
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results
Cogent Biosciences reported strong second-quarter 2026 financial results and significant progress toward the potential FDA approval of bezuclastinib for GIST and NonAdvSM later this year. The company announced the successful onboarding of its customer-facing team and a robust cash balance of $865.9 million, sufficient to fund operations into late 2028. Key milestones include NDA submissions, positive clinical trial data presentations for bezuclastinib, and advancements in its broader pipeline of precision therapies.
Press Release: Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results
Cogent Biosciences has announced its recent business highlights and financial results for the second quarter of 2026. The report will likely cover advancements in their drug development pipeline, particularly for rare diseases, and provide an overview of their financial performance, including revenue and expenses. This release is crucial for investors and stakeholders to understand the company's progress and financial health.
Cogent Biosciences set to report earnings ahead of FDA decisions
Cogent Biosciences is scheduled to report second-quarter earnings, with investors keenly watching for updates on its commercial launch preparations for bezuclastinib, its lead drug candidate, ahead of potential FDA approvals later this year. The company is transitioning from a clinical-stage to a marketed-drug business and analysts expect a wider loss of $0.555 per share. Regulatory progress, cash burn, and launch strategies will be key areas of focus as the stock has seen a significant surge over the past year.
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results
Cogent Biosciences announced its second-quarter 2026 financial results and provided key business highlights. The company is on track for potential FDA approval of bezuclastinib for GIST and Non-AdvSM later this year, with an AdvSM New Drug Application already submitted. Cogent also reported a strong cash balance of $865.9 million, sufficient to fund operations into late 2028, and detailed the successful onboarding of its commercial and medical teams.
Cogent Biosciences Q2 loss widens as bezuclastinib FDA deadlines approach
Cogent Biosciences (COGT) reported a widened net loss of $96.4 million in Q2 2026, up from $73.5 million in Q2 2025, driven by increased R&D and G&A expenses. The company has sufficient cash runway into late 2028 and is approaching key FDA PDUFA dates for bezuclastinib in GIST and NonAdvSM in November and December 2026, respectively. Insider trading activity shows significant sales, while institutional investors present a mixed picture of additions and reductions in COGT holdings.
Cogent Biosciences (COGT) widens Q2 loss but nears FDA decisions on bezuclastinib
Cogent Biosciences reported a wider net loss of $96.4 million in Q2 2026, up from $73.5 million in Q2 2025, primarily due to increased R&D and G&A expenses. Despite this, the company is advancing towards potential FDA approvals for bezuclastinib in GIST (November 30, 2026) and Advanced Systemic Mastocytosis (December 30, 2026), supported by positive pivotal trial data. Cogent Biosciences also highlighted a strong cash position of $865.9 million (pro forma), expected to fund operations into late 2028, including potential product launches.
Cogent’s Bezuclastinib Could Reach FDA Decisions in Nov., Dec.
Cogent Biosciences reported its Q2 2026 financial results, highlighting significant progress for its drug bezuclastinib with FDA New Drug Applications submitted for GIST and systemic mastocytosis. The company anticipates FDA decisions for GIST by November 30, 2026, and for NonAdvSM by December 30, 2026. Despite an increase in operating expenses and net loss, Cogent maintains a strong cash position of $865.9 million (pro forma) which is expected to fund operations into late 2028, supporting potential launches and pipeline advancement.
Cogent Biosciences, Inc. $COGT Shares Sold by Hennion & Walsh Asset Management Inc.
Hennion & Walsh Asset Management Inc. significantly reduced its stake in Cogent Biosciences (NASDAQ:COGT) by 59.6% in the second quarter, selling 194,697 shares but retaining 131,775 shares valued at approximately $5.1 million. Despite this sale, analyst sentiment for Cogent Biosciences remains positive with a "Moderate Buy" consensus and an average price target of $45.90. The company's stock opened at $42.39, near its 52-week high, and has a market capitalization of $7.24 billion.
Assenagon Asset Management S.A. Increases Stock Position in Cogent Biosciences, Inc. $COGT
Assenagon Asset Management S.A. significantly increased its stake in Cogent Biosciences, Inc. (NASDAQ:COGT) by 387.7% in the second quarter, now holding 1.44 million shares valued at $55.8 million. Other major institutional investors like Deerfield Management, RTW Investments, Vanguard, and T. Rowe Price also expanded their positions in the company. Cogent Biosciences shares are trading near their 12-month high, with analysts maintaining a "Moderate Buy" rating and an average price target of $45.90, despite the company being unprofitable.
If You Invested $100 In Cogent Biosciences Stock 5 Years Ago, You Would Have This Much Today
Cogent Biosciences (NASDAQ: COGT) has significantly outperformed the market over the past five years, with an annualized return of 40.76%. An initial investment of $100 in COGT stock five years ago would now be worth $584.69. This article highlights the power of compounded returns in investment growth over time.
Loss-Making Cogent Biosciences, Inc. (NASDAQ:COGT) Expected To Breakeven In The Medium-Term
This article analyzes Cogent Biosciences, Inc.'s financial performance and future prospects, focusing on its path to breakeven. Analysts project the company to reach profitability within two years, with significant revenue growth expected in the coming years. The piece also delves into the risks and opportunities associated with investing in high-growth, loss-making companies like Cogent.
Cogent Biosciences Gains as Investors Revisit Late-Stage Bezuclastinib Catalysts
Cogent Biosciences (COGT) shares rose 10.2% due to renewed investor optimism regarding its drug bezuclastinib and a busy regulatory schedule. The company recently submitted its third NDA for bezuclastinib in six months, with decisions for other applications expected later in 2026. Cogent is also preparing for dual commercial launches and reported strong cash reserves, easing near-term financing concerns.
Behavioral Patterns of COGT and Institutional Flows
This article analyzes Cogent Biosciences Inc. (NASDAQ: COGT) focusing on its behavioral patterns and institutional flows. Key findings indicate a near-term neutral sentiment amidst mid and long-term strength, with a notable 83.7:1 risk-reward setup. The analysis provides specific institutional trading strategies, including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for various horizons.
Seven Fleet Capital Management LP Sells 64,700 Shares of Cogent Biosciences, Inc. $COGT
Seven Fleet Capital Management LP significantly reduced its stake in Cogent Biosciences by selling 64,700 shares, retaining 149,399 shares valued at approximately $5.75 million. This divestment occurred while other institutional investors like Royal Bank of Canada and California State Teachers Retirement System increased their holdings. Cogent Biosciences reported quarterly EPS of negative $0.53, aligning with estimates, and analysts maintain a "Moderate Buy" rating with an average price target of $45.90.
Vanguard Capital Management discloses 5.08% Cogent Biosciences (COGT) ownership in 13G filing
Vanguard Capital Management LLC has filed a Schedule 13G, disclosing a beneficial ownership of 5.08% in Cogent Biosciences Inc (COGT), amounting to 8,691,589 shares. The filing indicates that Vanguard holds sole voting power over 1,279,259 shares and sole dispositive power over all 8,691,589 shares, with no shared voting or dispositive power. This ownership reflects holdings across various Vanguard funds and managed accounts, but no other individual entity holds more than a 5% interest.
COGT|Cogent Biosciences Inc|Price:39.585|Chg%:-1.085
This article provides a comprehensive stock analysis of Cogent Biosciences Inc (COGT) by TradingKey. It highlights the company's strong fundamentals, high growth potential, and high institutional ownership. The valuation is considered fairly valued, and analysts have issued a "Buy" rating with a target price indicating significant upside.
Cogent Biosciences Market Sentiment
This article analyzes market sentiment for Cogent Biosciences (COGT) based on analyst consensus, short interest, options flow, and insider activity. It highlights a "Buy" analyst consensus with 16 analysts, a 9.6% rising short float, and a bullish options flow with a 0.27 Put/Call ratio. The piece also details recent analyst actions, including price target changes and ratings.
Cogent Biosciences Inc (COGT) Financial Health: Profitability & Balance Sheet Analysis
This article provides a financial health analysis of Cogent Biosciences Inc (COGT) by TradingKey, focusing on its profitability and balance sheet. The company has a current financial score of 6.80, ranking 205 out of 384 in its industry, indicating robust financial status but low operational efficiency. Key financial metrics for Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholder Returns have not yet been disclosed by the company.
Cogent Biosciences Inc (COGT) Institutional Confidence
Cogent Biosciences Inc (COGT) has achieved an institutional shareholding score of 10.00, placing it first among 386 companies in the Biotechnology & Medical Research industry. The institutional shareholding proportion recently increased by 14.34% quarter-over-quarter, reaching 102.81%. Steven Cohen is the largest institutional shareholder, holding 6.61 million shares, which represents 3.47% of shares outstanding after a 320.25% increase in his holdings.
Cogent Biosciences Inc (COGT) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides historical dividend and stock split information for Cogent Biosciences Inc (COGT). It notes that COGT has distributed $0.00 in dividends over the past five years and details multiple 4-for-1 merger-related stock splits that occurred on November 6, 2020. The article also includes current stock performance and market capitalization data.
COGT|Cogent Biosciences Inc|Price:39.760|Chg%:-0.480
This article provides a detailed company profile for Cogent Biosciences Inc (COGT), a biotechnology firm focused on precision therapies for genetically defined diseases. It highlights their clinical program bezuclastinib, aimed at systemic mastocytosis, and other targeted therapies in development. The article also lists key company information, executive leadership, and institutional shareholding data.
Cogent Biosciences Inc (COGT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey provides a revenue breakdown for Cogent Biosciences Inc (COGT). It notes that relevant revenue data by business segment and region for FY2021 has not yet been disclosed by the company, though it lists the United States as a region with 0.00 revenue proportion. The article also includes current stock information for COGT.
Cogent Biosciences Inc (COGT) Shareholder Structure: Major Shareholders & Institutional Holdings
This article provides a detailed breakdown of Cogent Biosciences Inc.'s (COGT) shareholder structure, including major shareholders, shareholder types by proportion, and institutional holdings over several quarters. It lists top institutional investors like Fidelity, BlackRock, and Deerfield Management, alongside their proportional holdings and changes. The report also highlights related ETFs with COGT holdings.
COGT|Cogent Biosciences Inc|Price:39.760|Chg%:-0.480
Cogent Biosciences Inc. (COGT) closed at $39.76, down 1.19%. The company has strong fundamentals and high growth potential, with its valuation considered fairly priced within the Biotechnology & Medical Research industry. Analysts currently rate the stock as a "Buy" with a target price of $53.55, indicating a 35.08% upside.
Cogent Biosciences Inc (COGT) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Cogent Biosciences Inc (COGT) as of July 24, 2026. The company currently has a valuation score of 8.84, ranking 89th in its industry, and a P/E ratio of -18.40. Key metrics like P/B, P/CF, and specific P/E relevant data have not been disclosed by the company.
(COGT) Movement Within Algorithmic Entry Frameworks
This article provides an algorithmic analysis of Cogent Biosciences Inc. (NASDAQ: COGT), highlighting near-term strong sentiment potentially leading to mid-term neutrality and long-term positive bias. It outlines three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis and risk/reward parameters for traders. The analysis suggests a significant risk-reward short setup targeting 19.5% downside with minimal risk.
COGT6232219 Bond Risk Profile
This page provides a risk profile for the Cogent Biosciences, Inc. 1.625% 15-NOV-2031 bond, identified by FINRA COGT6232219. It offers an overview of the bond, focusing on credit risk assessment and key metrics for risk analysis. The platform also promises access to exclusive analyst ratings for bonds to help users make informed decisions.
COGT6232219 Bond Coupon Profile — Rate & Payments
This article provides a coupon profile for the Cogent Biosciences, Inc. bond COGT6232219, which has a 1.625% interest rate maturing on November 15, 2031. It details the current coupon rate of 1.63% and announces that the next payment is scheduled for November 16, 2026. The page offers an overview of interest payments and encourages users to unlock full coupon data for more insights.
COGT6232219 Bond Profile — Key Metrics
This article provides key metrics and an overview of the COGT6232219 bond issued by Cogent Biosciences, Inc. It details the bond's coupon rate, maturity date, issue date, outstanding amount, and face value. Additionally, it offers a brief description of Cogent Biosciences, Inc. as a biotechnology company.
Price to sales forward of Cogent Biosciences, Inc. – NASDAQ:COGT
This article provides financial information for Cogent Biosciences, Inc. (NASDAQ: COGT), specifically focusing on its Price to Sales forward metric. The content highlights that market data is provided by ICE Data Services and FactSet, and SEC filings are by Quartr.
(COGT) Movement Within Algorithmic Entry Frameworks
The article provides an algorithmic analysis of Cogent Biosciences Inc. (NASDAQ: COGT), highlighting strong sentiment across all time horizons and an exceptional risk-reward short setup. It details three trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels derived from AI models for different risk profiles.
Enterprise value to EBITDA forward of Cogent Biosciences, Inc. – NASDAQ:COGT
This article provides financial data specifically on the enterprise value to EBITDA forward for Cogent Biosciences, Inc. (NASDAQ: COGT). It appears to be a stub or data-focused page from a financial charting and analysis platform, presenting this specific metric for the company. The page also lists various sections related to financial markets, tools, and community features of the platform.
Cogent Biosciences (COGT) Files FDA Application As Bezuclastinib Hype Meets A Pricey Valuation
Cogent Biosciences has filed a New Drug Application (NDA) with the FDA for bezuclastinib, targeting Advanced Systemic Mastocytosis, following positive trial results. Despite strong recent share price performance, the company's valuation, at a 12.8x Price-to-Book ratio, is considered high compared to both direct peers and the broader biotech industry, suggesting caution is warranted due to inherent risks like regulatory setbacks and funding needs.
Is Bezuclastinib’s FDA Filing And Disease-Modifying Data Altering The Investment Case For Cogent Biosciences (COGT)?
Cogent Biosciences has submitted a New Drug Application to the FDA for bezuclastinib, supported by strong data from the APEX trial showing disease modification in advanced systemic mastocytosis. This filing, coupled with ongoing Expanded Access Programs, is a significant catalyst for the company, although it still faces challenges such as heavy ongoing losses and the need to successfully commercialize its late-stage programs. Investors should consider regulatory risks and the company's financial runway amidst its reliance on favorable FDA outcomes.
Price to book forward of Cogent Biosciences, Inc. – NASDAQ:COGT
This article provides financial data for Cogent Biosciences, Inc. (NASDAQ: COGT), specifically focusing on its forward price-to-book ratio. It is a financial data page from TradingView, offering an overview of the company's financials for investors and analysts. The page includes general market information, without specific numerical values in the provided snippet.
Is Bezuclastinib’s FDA Filing And Disease-Modifying Data Altering The Investment Case For Cogent Biosciences (COGT)?
Cogent Biosciences recently submitted a New Drug Application to the FDA for bezuclastinib, a drug for advanced systemic mastocytosis, backed by strong clinical trial data showing disease modification. While this strengthens the company's investment narrative by highlighting near-term regulatory catalysts, investors must weigh this against ongoing losses, dilution risk, and the challenges of commercialization with zero current revenue. The company's recent exclusion from Russell indexes might also introduce technical pressure, making regulatory outcomes and commercial execution critical for future growth.
